AstraZeneca.JPG” style=”padding: 10px” width=”235″ />AstraZeneca has signed an agreement with Roche Group subsidiary Bina Technologies to join the Bina Alliance Programme and advance development of the Bina Genomic Management Solution (GMS).
Bina GMS is a comprehensive analysis platform developed for clinical and translational researchers to gain insight from their genomic data sets.
Under the agreement, AstraZeneca will adopt Bina GMS to support enterprise genomic data analysis and management.
Bina Technologies CEO and founder Dr Narges Bani Asadi said: "In this collaboration, our multidisciplinary team of scientists and engineers will try to push the boundaries of genomics research.
"Through this collaboration, we both hope to define a new standard for the pharmaceutical research industry in how to effectively leverage the genomic information for discovery and development."
Under the deal, AstraZeneca will use Bina GMS as an enterprise platform, in a bid to support its development work across three main therapeutic areas, including oncology, cardiovascular and metabolic disease, and respiratory, inflammation and autoimmunity.
Bina’s scientific and engineering teams will also work with AstraZenec to further develop the Bina GMS for pharmaceutical applications.
AstraZeneca principal translational genomic scientist Justin Johnson said: "In working with Bina, we can not only significantly accelerate the speed in which we incorporate genomic data into areas like target discovery and patient selection, but we can do this on top of a flexible, scalable and validated analysis infrastructure that our bench scientists can work with."
Johnson will present the early results of the partnership during the Cambridge Healthtech Institute’s 14th Annual Bio-IT World Conference and Expo in Boston, US, which will be held on 23 April.
Image: AstraZeneca’s R&D site in Mölndal, Sweden. Photo: courtesy of Erik031.
